Novel approaches to pediatric vaccine delivery

被引:28
作者
O'Hagan, DT
Rappuoli, R
机构
[1] Chiron Vaccines, Oakland, CA 94608 USA
[2] Chiron Vaccines, I-53100 Siena, Italy
关键词
vaccine delivery; vaccine adjuvants; needle-free immunization; topical immunization;
D O I
10.1016/j.addr.2005.12.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although currently available vaccines represent an outstanding success story in modem medicine and have had a dramatic effect on morbidity and mortality worldwide, it is clear that improvements in vaccine delivery are required. Vaccine delivery improvements may include the addition of novel injectable adjuvants, or the use of novel routes of delivery, including mucosal immunization. Mucosal delivery may be required to provide protection against pathogens that infect at mucosal sites, including sexually transmitted diseases. Alternatively, novel approaches to delivery, including mucosal administration, may be used to improve compliance for existing vaccines. Of particular interest for safer mass immunization are needle-free delivery devices, which would avoid problems due to needle re-use in many parts of the world, or needle-stick injuries. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:29 / 51
页数:23
相关论文
共 163 条
  • [1] Targeting to macrophages:: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages
    Ahsan, FL
    Rivas, IP
    Khan, MA
    Suárez, AIT
    [J]. JOURNAL OF CONTROLLED RELEASE, 2002, 79 (1-3) : 29 - 40
  • [2] PLGA microspheres containing plasmid DNA: Preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization
    Ando, S
    Putnam, D
    Pack, DW
    Langer, R
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (01) : 126 - 130
  • [3] Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines
    Arrington, J
    Braun, RP
    Dong, LC
    Fuller, DH
    Macklin, MD
    Umlauf, SW
    Wagner, SJ
    Wu, MS
    Payne, LG
    Haynes, JR
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (09) : 4536 - 4546
  • [4] THE INFLUENCE OF ANTIGEN ORGANIZATION ON B-CELL RESPONSIVENESS
    BACHMANN, MF
    ROHRER, UH
    KUNDIG, TM
    BURKI, K
    HENGARTNER, H
    ZINKERNAGEL, RM
    [J]. SCIENCE, 1993, 262 (5138) : 1448 - 1451
  • [5] Neutralizing antiviral B cell responses
    Bachmann, MF
    Zinkernagel, RM
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 : 235 - 270
  • [6] Controllers of the immune system and a new promise for immunotherapy
    Banchereau, J
    Paczesny, S
    Blanco, P
    Bennett, L
    Pascual, V
    Fay, J
    Palucka, AK
    [J]. IMMUNE MECHANISMS AND DISEASE, 2003, 987 : 180 - 187
  • [7] A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity meta-analysis
    Banzhoff, A
    Nacci, P
    Podda, A
    [J]. GERONTOLOGY, 2003, 49 (03) : 177 - 184
  • [8] Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization
    Barackman, JD
    Ott, G
    Pine, S
    O'Hagan, DT
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2001, 8 (03) : 652 - 657
  • [9] Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles
    Baudner, BC
    Balland, O
    Giuliani, MM
    Von Hoegen, P
    Rappuoli, R
    Betbeder, D
    Del Giudice, G
    [J]. INFECTION AND IMMUNITY, 2002, 70 (09) : 4785 - 4790
  • [10] The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines
    Baudner, BC
    Giuliani, MM
    Verhoef, JC
    Rappuoli, R
    Junginger, HE
    Del Giudice, G
    [J]. VACCINE, 2003, 21 (25-26) : 3837 - 3844